Salubris Pharmaceuticals Gains NMPA Approval for Phase I Study of SAL0133
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving approval from the National...
Kactus Biosystems Partners with Bioheng for Cell Therapy Raw Materials
Shanghai-based Kactus Biosystems, a firm specializing in target proteins and raw enzymes, has announced a...
Immune-Onc Therapeutics Completes $131 Million Series B Financing
US-headquartered Immune-Onc Therapeutics, Inc. has announced the successful completion of a Series B financing round...
Henlius Completes First Dosing in Global Phase III Study for HanSiZhuang in LS-SCLC
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...
Singular Medical Secures Series B+ Funding for Cardiac Device Development
Singular Medical, a Suzhou-based maker of cardiac rhythm and heart failure devices, has reportedly raised...
Boehringer Ingelheim Enrolls First Patient in Phase II/III Study for BI 907828
German pharmaceutical giant Boehringer Ingelheim has announced the enrollment of the first patient in the...
Vcanbio’s Stem Cell Therapy VUM02 Accepted for Clinical Trial Review
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...
CanSino Biologics’ mRNA Vaccine CS-2034 Shows Positive Safety and Immunogenicity Data
China-based CanSino Biologics (HKG: 6185) has announced positive periodical data from a clinical study assessing...
Mindray Partners with BOMImed for Exclusive Canadian Sales and Service
China-based medical device giant Mindray’s North American unit has announced a partnership with Canadian biomedical...
Simnova Partners with Orna Therapeutics for In Situ CAR Therapies
Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has announced a...
Aurisco Partners with Cytiva to Build Oligonucleotide Production Plant
China-based contract development and manufacturing organization (CDMO) Aurisco Pharmaceutical Co., Ltd has revealed plans to...
Jiangsu Aidea’s ACC007 Approved by NMPA for HIV-1 Treatment
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that its Category 1 compound...
WuXi Biologics and GSK Ink Licensing Agreement for T-Cell Engaging Antibodies
China-based WuXi Biologics (HKG: 2269) has announced a licensing agreement with GSK plc (NYSE: GSK),...
Antengene Acquires Full Rights to Calithera’s CD73 Inhibitor CB-708
China-based Antengene Corporation Ltd (HKG: 6996) has unveiled a transfer agreement with US-headquartered Calithera Biosciences...
Haisco’s EGFR-PROTAC HSK40118 Accepted for Review by China’s NMPA
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...
Duality Biologics Licenses ADC Platform to Denmark’s Adcendo for Mesenchymal Tumor Program
Duality Biologics, a developer of novel modality drugs operating in the United States and China,...
NMPA Strengthens Oversight of COVID-19 Drugs and Home Treatment Guidelines
The National Medical Products Administration (NMPA) has released a notification aimed at enhancing the quality...
NMPA Approves Chinabridge’s ECMO Equipment for Emergency Use
The National Medical Products Administration (NMPA) has approved Chinabridge (Shenzhen) Medical Technology Co., Ltd’s extracorporeal...
EOC Pharma’s Entinostat NDA Accepted by China’s NMPA for Breast Cancer
EOC Pharma, a biotech company operating in the US and China, has announced that its...
HighTide Therapeutics Completes $107 Million Series C and C+ Financing Rounds
China-based HighTide Therapeutics Inc. has announced the completion of Series C and C+ financing rounds,...